Literature DB >> 20075159

Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors.

Olga Ostrovsky1, Avichai Shimoni, Avital Rand, Israel Vlodavsky, Arnon Nagler.   

Abstract

Graft-versus-host disease (GVHD) is the most common cause of nonrelapse mortality and morbidity after hematopoietic stem cell transplantation (HSCT). The well-documented involvement of heparanase in the process of inflammation and autoimmunity led us to investigate an association between HPSE gene single-nucleotide polymorphisms (SNPs) and the risk of GVHD. The present study indicates a highly significant correlation of HPSE gene SNPs rs4693608 and rs4364254 and their combination with the risk of developing acute GVHD. Moreover, the study revealed that discrepancy between recipient and donor in these SNPs may elevate significantly the risk of acute GVHD. This association was statistically significant when the recipients possessed genotype combinations dictating higher levels of heparanase compared with their human leukocyte antigen (HLA)-matched donors. In addition, HPSE gene SNPs disclosed a correlation with extensive chronic GVHD, nonrelapse mortality, and overall survival. Our study indicates involvement of heparanase in the development of acute and extensive chronic GVHD. Moreover, it suggests a possible mechanism for the aggressive behavior of T lymphocytes leading to GVHD when the recipients possess genotype combinations that dictate high levels of heparanase mRNA compared with their HLA-matched donors expressing low levels of heparanase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20075159      PMCID: PMC2844015          DOI: 10.1182/blood-2009-08-236455

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

Review 1.  Heparanase: a key enzyme involved in cell invasion.

Authors:  C R Parish; C Freeman; M D Hulett
Journal:  Biochim Biophys Acta       Date:  2001-03-21

Review 2.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

3.  Heparanase as mediator of angiogenesis: mode of action.

Authors:  M Elkin; N Ilan; R Ishai-Michaeli; Y Friedmann; O Papo; I Pecker; I Vlodavsky
Journal:  FASEB J       Date:  2001-07       Impact factor: 5.191

Review 4.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.

Authors:  I Vlodavsky; Y Friedmann
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

5.  Heparanase expression in human leukemias is restricted to acute myeloid leukemias.

Authors:  Menachem Bitan; Aaron Polliack; Gabriella Zecchina; Arnon Nagler; Yael Friedmann; Liat Nadav; Varda Deutsch; Iris Pecker; Amiram Eldor; Israel Vlodavsky; Ben-Zion Katz
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

6.  Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation.

Authors:  J Cavet; A M Dickinson; J Norden; P R Taylor; G H Jackson; P G Middleton
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

Review 7.  Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation.

Authors:  G G Vaday; O Lider
Journal:  J Leukoc Biol       Date:  2000-02       Impact factor: 4.962

8.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

9.  Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation.

Authors:  Vanderson Rocha; Rendrik F Franco; Raphael Porcher; Henrique Bittencourt; Wilson A Silva; Aurelien Latouche; Agnes Devergie; Helene Esperou; Patricia Ribaud; Gerard Socie; Marco Antonio Zago; Eliane Gluckman
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

Review 10.  Modulation of leukocyte behavior by an inflamed extracellular matrix.

Authors:  H Schor; G G Vaday; O Lider
Journal:  Dev Immunol       Date:  2000
View more
  28 in total

Review 1.  Evaluation of published single nucleotide polymorphisms associated with acute GVHD.

Authors:  Jason W Chien; Xinyi Cindy Zhang; Wenhong Fan; Hongwei Wang; Lue Ping Zhao; Paul J Martin; Barry E Storer; Michael Boeckh; Edus H Warren; John A Hansen
Journal:  Blood       Date:  2012-01-26       Impact factor: 22.113

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

Review 3.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

Review 4.  NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges.

Authors:  Smita Bhatia; Stella M Davies; K Scott Baker; Michael A Pulsipher; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-18       Impact factor: 5.742

5.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Authors:  Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

6.  Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Authors:  Paul J Martin; Wenhong Fan; Barry E Storer; David M Levine; Lue Ping Zhao; Edus H Warren; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Michael Boeckh; Sangeeta Hingorani; Li Yan; Qiang Hu; Leah Preus; Song Liu; Stephen Spellman; Xiaochun Zhu; Marcelo Pasquini; Philip McCarthy; Daniel Stram; Xin Sheng; Loreall Pooler; Christopher A Haiman; Lara Sucheston-Campbell; Theresa Hahn; John A Hansen
Journal:  Blood       Date:  2016-10-06       Impact factor: 22.113

7.  Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Authors:  Menachem Bitan; Lola Weiss; Michael Zeira; Eyal Zcharia; Shimon Slavin; Arnon Nagler; Israel Vlodavsky
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

Review 8.  Biologic markers of chronic GVHD.

Authors:  J Pidala; M Sarwal; S Roedder; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-07-22       Impact factor: 5.483

Review 9.  The major histocompatibility complex: a model for understanding graft-versus-host disease.

Authors:  Effie W Petersdorf
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

10.  Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.

Authors:  Paul G Richardson; Vincent T Ho; Sergio Giralt; Sally Arai; Shin Mineishi; Corey Cutler; Joseph H Antin; Nicole Stavitzski; Dietger Niederwieser; Ernst Holler; Enric Carreras; Robert Soiffer
Journal:  Ther Adv Hematol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.